Clinical Commander

Back to dossier
cardio.cardiac-tamponade.purulent-bacterial.v1PRODUCTION
cardio.cardiac-tamponade.purulent-bacterial.v1

Cardiac tamponade — purulent bacterial pericarditis

cardiologyacuteadult
Hard-required inputs
0 / 11
Care setting:

Encounter flow

9/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Purulent bacterial tamponade — EMERGENT drainage (subxiphoid window preferred over needle alone for thick pus + loculations) + immediate empiric IV antibiotics covering MRSA + streptococci + gram-negatives + source control + intrapericardial fibrinolytics to prevent constriction; mortality 40-77% even with optimal therapy (ESC 2015; Pankuweit Heart 2013 PMID 23257306)

Inputs
1
Actions
0
Advance rule
Set
Advance when

purulent-context tamponade physiology suspected

Patient inputs (11)

Older + immunocompromised patients have higher mortality + atypical organism distribution (Pankuweit Heart 2013 PMID 23257306)

Compensatory tachycardia + sepsis-driven tachycardia (ESC 2015)

Pneumonia, empyema, mediastinitis, endocarditis, dental sepsis, bacteremia, recent cardiothoracic / esophageal surgery, HIV, chemo, ESRD — drives empiric antibiotic + surgical strategy (ESC 2015; Augustin EJCTS 2011)

Fever is a defining feature; quantify pattern + height; absent fever in elderly / immunocompromised does NOT exclude (Pankuweit Heart 2013)

Definitive bedside dx — chamber collapse, IVC, swinging heart; thick fibrinous loculated pattern characteristic of purulent etiology (ESC 2015 Class I)

Sepsis-driven hypoperfusion marker; ≥2 mmol/L drives sepsis bundle activation per Surviving Sepsis 2026

Leukocytosis with left shift typical; leukopenia in severe sepsis / immunocompromised — both ominous (Pankuweit Heart 2013)

Baseline for vancomycin AUC dosing + sepsis-related AKI tracking + contrast for chest CT (IDSA 2024 MRSA)

Sepsis / DIC platelet consumption + drainage bleeding risk (Surviving Sepsis 2026)

CXR + low-threshold chest CT to identify primary source (pneumonia, empyema, mediastinal abscess, esophageal perforation); positive findings strengthen diagnosis + guide source control (ESC 2015 §Purulent)

Hypotension is part of Beck triad; superimposed septic shock in purulent pericarditis (Surviving Sepsis 2026)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningseptic_shock_with_tamponade_dual_hit_requiring_concurrent_drainage_and_sepsis_bundle
    Hypotension with MAP <65 + lactate ≥4 + tamponade physiology — DUAL OBSTRUCTIVE + SEPTIC shock requiring emergent simultaneous management (Surviving Sepsis 2026; ESC 2015)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninginadequate_drainage_with_persistent_loculation_despite_catheter_and_fibrinolytics
    Persistent loculated purulent effusion despite pericardiocentesis catheter + intrapericardial fibrinolytics × 3-5 days — surgical pericardiectomy mandatory (ESC 2015 §Purulent; Augustin EJCTS 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremrsa_or_mdr_organism_requiring_alternative_or_extended_therapy
    MRSA, MDR gram-negative (ESBL, CRE), or VRE confirmed on culture — empiric regimen needs expansion or substitution (IDSA 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereconstrictive_pericarditis_development_post_recovery
    Constrictive pericarditis physiology developing during or after IV antibiotic completion — ~25-35% of purulent pericarditis develop constriction requiring pericardiectomy (ESC 2015 Class IIa; Pankuweit Heart 2013 PMID 23257306)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereconcurrent_endocarditis_or_mediastinitis_requiring_extended_antibiotics_and_surgery
    Hematogenous purulent pericarditis with confirmed endocarditis (TEE positive) OR contiguous spread from mediastinitis (CT confirmed) — extended antibiotics 6-8 wk + concurrent surgical management of primary source (ESC 2023 Endocarditis PMID 37622656; Augustin EJCTS 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Purulent bacterial pericarditis — emergent surgical drainage + empiric vancomycin + ceftriaxone (expand for nosocomial / post-surgical) + intrapericardial fibrinolytics + sepsis bundle (ESC 2015; Pankuweit Heart 2013 PMID 23257306; Surviving Sepsis 2026)
axis: purulent_pericardial_emergent_drainage_plus_empiric_iv_antibiotics_plus_source_control
Selected axis "Purulent bacterial pericarditis — emergent surgical drainage + empiric vancomycin + ceftriaxone (expand for nosocomial / post-surgical) + intrapericardial fibrinolytics + sepsis bundle (ESC 2015; Pankuweit Heart 2013 PMID 23257306; Surviving Sepsis 2026)" by default fallback (first axis)
  • vancomycin
    first line
    glycopeptide_antibiotic_mrsa_coverage
    loading 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h targeting AUC 400-600 mg·h/L • IV • q8-12h with AUC monitoring
    triggers: empiric_coverage_for_s_aureus_including_mrsa, streptococci_methicillin_resistant_concern
    IDSA 2024 MRSA bacteremia — first-line empiric for purulent pericarditis given S. aureus ~50% etiology; AUC-targeted dosing reduces nephrotoxicity vs trough-only
    rxcui 11124
  • ceftriaxone
    first line
    cephalosporin_3rd_gen
    2 g IV q24h (q12h for CNS / endocarditis source overlap) • IV • q24h
    triggers: empiric_coverage_for_streptococci_and_susceptible_gram_negatives
    ESC 2015 + Pankuweit 2013 — first-line for community-acquired purulent pericarditis covering S. pneumoniae + susceptible gram-negatives + N. meningitidis
    rxcui 2193
  • cefepime
    second line
    cephalosporin_4th_gen_anti_pseudomonal
    2 g IV q8h • IV • q8h
    triggers: nosocomial_or_post_thoracic_surgery_or_immunocompromised
    Anti-Pseudomonal coverage for healthcare-associated / post-cardiothoracic surgery / neutropenic patients per IDSA 2024 + Augustin EJCTS 2011
    rxcui 20481
  • piperacillin-tazobactam
    second line
    penicillin_beta_lactamase_inhibitor_anti_pseudomonal
    4.5 g IV q6h (extended infusion preferred) • IV • q6h extended infusion
    triggers: nosocomial_or_post_thoracic_surgery_or_anaerobic_concern
    Alternative anti-Pseudomonal + anaerobic coverage for nosocomial / post-surgical purulent pericarditis (Surviving Sepsis 2026)
    rxcui 74169
  • metronidazole
    add on
    nitroimidazole_anaerobic
    500 mg IV q8h • IV • q8h
    triggers: esophageal_perforation_dental_source_or_anaerobic_suspected
    Anaerobic coverage for esophageal perforation / dental sepsis spread / mediastinitis (ESC 2015 §Purulent; Augustin EJCTS 2011)
    rxcui 6922
  • linezolid
    contraindication substitute
    oxazolidinone_mrsa_alternative
    600 mg IV q12h • IV • q12h
    triggers: vancomycin_intolerance_or_van_resistant_enterococcus
    IDSA 2024 alternative to vancomycin for MRSA when intolerance, AUC unachievable, or VRE confirmed; serotonergic + thrombocytopenia surveillance
    rxcui 190376
  • streptokinase
    add on
    fibrinolytic_intrapericardial
    250,000-500,000 U intrapericardial via catheter • intrapericardial • q24h × 3-7d via catheter
    triggers: fibrinous_loculated_purulent_effusion_to_prevent_constriction
    Maisch ESC 2004 + Tomkowski Cardiology 2008 — intrapericardial fibrinolytics dissolve fibrin loculations + facilitate complete drainage + reduce constriction risk
    rxcui 10106
  • alteplase
    add on
    fibrinolytic_intrapericardial_alternative
    10-25 mg intrapericardial via catheter • intrapericardial • q24h × 3-7d
    triggers: streptokinase_unavailable_or_prior_streptokinase_exposure
    tPA alternative to streptokinase for intrapericardial fibrinolysis (Tomkowski 2008); preferred if prior streptokinase exposure (allergic/antibody risk)
    rxcui 8410
  • normal saline
    first line
    isotonic_crystalloid
    30 mL/kg over first 3h if MAP <65 and lactate ≥4 • IV • goal-directed bolus then reassess
    triggers: septic_shock_with_tamponade_dual_hit
    Surviving Sepsis 2026 — sepsis bundle 30 mL/kg crystalloid for hypotension; CAUTIOUS in tamponade (preload-dependent but volume overload risk if RH dysfunction)
    rxcui 9863
  • norepinephrine
    first line
    vasopressor_alpha_predominant
    0.05-0.1 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_septic_or_tamponade_hypotension
    Surviving Sepsis 2026 + ESC 2015 — first-line vasopressor for both septic and obstructive shock; bridge to drainage + source control
    rxcui 7512

outpatient playbook — drug actions (4)

  1. 1. continue IV antibiotics until 4-6 wk total + final cure documentation
    rxcui 11124
    organism-targeted • IV via PICC • per agent
    trigger: OPAT continuation
    Pankuweit 2013 — 4-6 wk standard; extend if endocarditis source
  2. 2. completion of IV antibiotics + PICC removal
    completed • N/A • completed
    trigger: End of 4-6 wk course
    ESC 2015 — narrow to PO step-down NOT recommended for purulent pericarditis given high recurrence
  3. 3. pneumococcal vaccination if community-acquired pneumonia source
    PCV20 if not previously vaccinated • IM • one-time
    trigger: Pneumococcal source identified
    CDC ACIP 2024 — secondary prevention
  4. 4. diuretic for constriction symptoms if developing
    rxcui 4603
    furosemide 20-40 mg PO daily titrate • PO • daily
    trigger: Constriction symptoms developing
    Symptomatic relief while pericardiectomy evaluated (ESC 2015)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Septic-appearing patient (fever, tachycardia, hypotension) with pericardial effusion + Beck triad — purulent pericarditis until proven otherwise; mortality 40-77% (ESC 2015 §Purulent Pericarditis; Pankuweit Heart 2013 PMID 23257306); Pneumonia / empyema (especially S. pneumoniae or staph) developing new pericardial effusion → contiguous spread purulent pericarditis (Sagristà-Sauleda EHJ 2002 PMID 12122206); Post-cardiothoracic surgery (CABG, valve, esophagectomy) within 30 days with new pericardial effusion + sternal wound drainage / fever / leukocytosis → mediastinitis with contiguous spread (gram-negatives + MRSA; Augustin EJCTS 2011).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — purulent bacterial pericarditis** (cardio.cardiac-tamponade.purulent-bacterial.v1).
Phenotype framing: Pericardial fluid analysis: PMN-predominant (>10,000/μL), glucose <40 mg/dL, LDH high, protein high, gram stain + culture (aerobic + anaerobic + fungal + AFB), cytology, ADA (excludes TB), MALDI-TOF / 16S PCR for organism identification; blood cultures + source-site cultures (sputum, urine, wound, sternal swab) (Pankuweit Heart 2013; ESC 2015)
Scope: Purulent bacterial tamponade — EMERGENT drainage (subxiphoid window preferred over needle alone for thick pus + loculations) + immediate empiric IV antibiotics covering MRSA + streptococci + gram-negatives + source control + intrapericardial fibrinolytics to prevent constriction; mortality 40-77% even with optimal therapy (ESC 2015; Pankuweit Heart 2013 PMID 23257306)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Purulent bacterial pericarditis — emergent surgical drainage + empiric vancomycin + ceftriaxone (expand for nosocomial / post-surgical) + intrapericardial fibrinolytics + sepsis bundle (ESC 2015; Pankuweit Heart 2013 PMID 23257306; Surviving Sepsis 2026)**.
1. vancomycin loading 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h targeting AUC 400-600 mg·h/L IV q8-12h with AUC monitoring (glycopeptide_antibiotic_mrsa_coverage, first line) — IDSA 2024 MRSA bacteremia — first-line empiric for purulent pericarditis given S. aureus ~50% etiology; AUC-targeted dosing reduces nephrotoxicity vs trough-only
2. ceftriaxone 2 g IV q24h (q12h for CNS / endocarditis source overlap) IV q24h (cephalosporin_3rd_gen, first line) — ESC 2015 + Pankuweit 2013 — first-line for community-acquired purulent pericarditis covering S. pneumoniae + susceptible gram-negatives + N. meningitidis
3. cefepime 2 g IV q8h IV q8h (cephalosporin_4th_gen_anti_pseudomonal, second line) — Anti-Pseudomonal coverage for healthcare-associated / post-cardiothoracic surgery / neutropenic patients per IDSA 2024 + Augustin EJCTS 2011
4. piperacillin-tazobactam 4.5 g IV q6h (extended infusion preferred) IV q6h extended infusion (penicillin_beta_lactamase_inhibitor_anti_pseudomonal, second line) — Alternative anti-Pseudomonal + anaerobic coverage for nosocomial / post-surgical purulent pericarditis (Surviving Sepsis 2026)
5. metronidazole 500 mg IV q8h IV q8h (nitroimidazole_anaerobic, add on) — Anaerobic coverage for esophageal perforation / dental sepsis spread / mediastinitis (ESC 2015 §Purulent; Augustin EJCTS 2011)
6. linezolid 600 mg IV q12h IV q12h (oxazolidinone_mrsa_alternative, contraindication substitute) — IDSA 2024 alternative to vancomycin for MRSA when intolerance, AUC unachievable, or VRE confirmed; serotonergic + thrombocytopenia surveillance
7. streptokinase 250,000-500,000 U intrapericardial via catheter intrapericardial q24h × 3-7d via catheter (fibrinolytic_intrapericardial, add on) — Maisch ESC 2004 + Tomkowski Cardiology 2008 — intrapericardial fibrinolytics dissolve fibrin loculations + facilitate complete drainage + reduce constriction risk
8. alteplase 10-25 mg intrapericardial via catheter intrapericardial q24h × 3-7d (fibrinolytic_intrapericardial_alternative, add on) — tPA alternative to streptokinase for intrapericardial fibrinolysis (Tomkowski 2008); preferred if prior streptokinase exposure (allergic/antibody risk)
9. normal saline 30 mL/kg over first 3h if MAP <65 and lactate ≥4 IV goal-directed bolus then reassess (isotonic_crystalloid, first line) — Surviving Sepsis 2026 — sepsis bundle 30 mL/kg crystalloid for hypotension; CAUTIOUS in tamponade (preload-dependent but volume overload risk if RH dysfunction)
10. norepinephrine 0.05-0.1 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor_alpha_predominant, first line) — Surviving Sepsis 2026 + ESC 2015 — first-line vasopressor for both septic and obstructive shock; bridge to drainage + source control

Setting playbook (outpatient) — Long-term surveillance for constrictive pericarditis (~25-35% develop); IV antibiotic completion at 4-6 wk; pericardiectomy if constriction develops; vaccination + risk-factor reduction (ESC 2015; Pankuweit 2013)
11. continue IV antibiotics until 4-6 wk total + final cure documentation organism-targeted IV via PICC per agent — OPAT continuation (Pankuweit 2013 — 4-6 wk standard; extend if endocarditis source)
12. completion of IV antibiotics + PICC removal completed N/A completed — End of 4-6 wk course (ESC 2015 — narrow to PO step-down NOT recommended for purulent pericarditis given high recurrence)
13. pneumococcal vaccination if community-acquired pneumonia source PCV20 if not previously vaccinated IM one-time — Pneumococcal source identified (CDC ACIP 2024 — secondary prevention)
14. diuretic for constriction symptoms if developing furosemide 20-40 mg PO daily titrate PO daily — Constriction symptoms developing (Symptomatic relief while pericardiectomy evaluated (ESC 2015))

Non-pharmacologic actions:
- ID follow-up weekly during OPAT then at 1 mo + 3 mo post-completion
- Cardiology follow-up at 4 wk + 8 wk + 12 wk + 6 mo + 12 mo then annually × 5 yr (constriction surveillance)
- Cardiothoracic surgery referral if constriction physiology develops (~25-35%)
- Vaccination update (pneumococcal, influenza, COVID-19)
- Patient + family education ongoing for constriction recognition

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain (ESC 2015)
- Needle_pericardiocentesis_alone_INADEQUATE_for_thick_purulent_fluid_subxiphoid_window_preferred (ESC 2015 §Purulent)
- Vancomycin_AUC_target_400_600_to_avoid_nephrotoxicity (IDSA 2024 MRSA)
- Streptokinase_AVOID_prior_exposure_within_6_mo_or_known_antibody (drug label)
- Aminoglycosides_AVOID_initial_empiric_in_purulent_unless_resistant_gram_negative_documented (Surviving Sepsis 2026)
- Colchicine_NOT_applicable_no_evidence_in_purulent_etiology (Imazio NEJM 2013 PMID 23992557)
- NSAIDs_AVOID_acute_phase_sepsis_AKI_bleeding_risk (Surviving Sepsis 2026)
- Steroids_NOT_first_line_in_purulent_only_if_septic_shock_refractory_per_sepsis_protocols (Surviving Sepsis 2026)
- Antibiotic_de_escalation_within_48_72h_per_culture_susceptibility_to_avoid_resistance (IDSA 2024)

Monitoring

Regimen monitoring:
- continuous ECG during drainage (ESC 2015)
- art line BP pre and post (Adler 2015)
- echo post drain immediate then q12 24h x 72h then daily (re-accumulation common in purulent)
- drainage output volume and character q1h initially then q4h (Pankuweit 2013)
- pericardial fluid analysis gram stain culture pmn glucose ldh cytology adam 16s pcr (ESC 2015)
- blood cultures daily until 2 consecutive negative (IDSA 2024)
- vancomycin AUC 400 600 or trough 15 20 mcg mL (IDSA 2024)
- serum creatinine daily (sepsis AKI + vancomycin nephrotoxicity)
- lactate q4h until normalized (Surviving Sepsis 2026)
- CRP procalcitonin q48h for treatment response (Pankuweit 2013)
- serial chest CT at 7d for source control assessment (Augustin EJCTS 2011)
- echo at 4 wk for constriction surveillance 25 35 percent risk (ESC 2015)

Setting (outpatient) monitoring:
- Echo at 4, 8, 12 wk then 6, 12 mo then annually × 5 yr
- CMR + RH cath if constriction physiology suspected
- CBC + BMP + Cr per ID

Monitoring phase: Re-accumulation surveillance (echo q12-24h initially then daily then per response); drainage output + character; daily blood cultures until clearance; CRP / procalcitonin trend; serial chest CT at 7d for source-control assessment; vancomycin AUC + trough monitoring; constriction surveillance (ESC 2015 §Follow-up; Pankuweit Heart 2013)

Disposition

Current setting: outpatient — Long-term surveillance for constrictive pericarditis (~25-35% develop); IV antibiotic completion at 4-6 wk; pericardiectomy if constriction develops; vaccination + risk-factor reduction (ESC 2015; Pankuweit 2013)

Disposition criteria:
- Long-term continuation under multidisciplinary team; pericardiectomy if constriction develops; cross-link to cardio.cardiac-tamponade.core.v1 for acute recurrence pathway

Escalation triggers (move to higher acuity):
- Symptomatic constrictive pericarditis (NYHA II-IV with constrictive physiology on imaging) → cardiothoracic surgery for pericardiectomy (Class IIa per ESC 2015; ~25-35% develop)
- Recurrent purulent effusion → emergent re-drainage + ID workup + extended antibiotics
- Antibiotic-associated complications (C. diff, AKI sequelae) → targeted management
- Effusive-constrictive pattern post-drainage → CMR + cardiothoracic for pericardiectomy evaluation

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Hypotension with MAP <65 + lactate ≥4 + tamponade physiology — DUAL OBSTRUCTIVE + SEPTIC shock requiring emergent simultaneous management (Surviving Sepsis 2026; ESC 2015)
- [LIFE_THREATENING] Persistent loculated purulent effusion despite pericardiocentesis catheter + intrapericardial fibrinolytics × 3-5 days — surgical pericardiectomy mandatory (ESC 2015 §Purulent; Augustin EJCTS 2011)
- [SEVERE] MRSA, MDR gram-negative (ESBL, CRE), or VRE confirmed on culture — empiric regimen needs expansion or substitution (IDSA 2024)

Citations

- 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Purulent Pericarditis — remains current as of 2026-05-15. Pankuweit Heart 2013 PMID 23257306 anchors modern diagnostic + management framework; Surviving Sepsis Campaign 2026 update anchors antibiotic-within-1h + sepsis bundle + dual-shock management; IDSA 2024 MRSA bacteremia guideline anchors vancomycin AUC-targeted dosing + alternatives; Maisch ESC 2004 + Tomkowski Cardiology 2008 anchor intrapericardial fibrinolytics; Augustin EJCTS 2011 anchors surgical pericardiectomy in purulent. [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 23257306) [PMID:23257306](https://pubmed.ncbi.nlm.nih.gov/23257306/)
- Cited evidence (PMID 12122206) [PMID:12122206](https://pubmed.ncbi.nlm.nih.gov/12122206/)
- Cited evidence (PMID 17456823) [PMID:17456823](https://pubmed.ncbi.nlm.nih.gov/17456823/)
- Cited evidence (PMID 20656240) [PMID:20656240](https://pubmed.ncbi.nlm.nih.gov/20656240/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Purulent Pericarditis — remains current as of 2026-05-15. Pankuweit Heart 2013 PMID 23257306 anchors modern diagnostic + management framework; Surviving Sepsis Campaign 2026 update anchors antibiotic-within-1h + sepsis bundle + dual-shock management; IDSA 2024 MRSA bacteremia guideline anchors vancomycin AUC-targeted dosing + alternatives; Maisch ESC 2004 + Tomkowski Cardiology 2008 anchor intrapericardial fibrinolytics; Augustin EJCTS 2011 anchors surgical pericardiectomy in purulent. — PMID:26320112
  • Cited evidence (PMID 23257306) — PMID:23257306
  • Cited evidence (PMID 12122206) — PMID:12122206
  • Cited evidence (PMID 17456823) — PMID:17456823
  • Cited evidence (PMID 20656240) — PMID:20656240